Research & Development: Page 39

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Agencies Pay It Forward

    In an open letter to CEOs earlier this year, BlackRock CEO and financial wizard Larry Fink outlined the need for companies to start focusing on the world outside their walls and find a way to serve a larger societal purpose. His thought process is that while focusing on building revenue, companie...

    By PharmaVoice Team • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trial Sites and Patient Diversity

    Having a diverse patient population in clinical trials is important because medicines affect people differently based on age, sex, and race. Biologic, genetic, and even cultural differences between patients can impact how a treatment will actually work in practice. Industry experts say the racial...

    By Denise Myshko • Oct. 1, 2018
  • clinical trial diversity Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Red Zone: Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites

    Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit" sites and returned to them f...

    By WCG Clinical Services • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    In the People Business According to PhRMA, 74% of the medicines in clinical development are potentially first-in-class medicines, meaning they represent a possible new pharmacological class for treating a medical condition. Furthermore, PhRMA reports that there are 822 projects, defined as unique...

    By Taren Grom • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    A Potential Treatment for Autism Kevin Sanders, M.D., Principal Medical Director of the Autism Program at Roche, talks about the company’s research program for balovaptan, which is being investigated to help improve social interaction and communication in people with autism. Autism, a lifelong de...

    By PharmaVoice Team • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    Innovation: As Many Questions As Answers John Nosta, President and Founder of Nosta Labs, challenges the status quo in discussing the state of innovation in the industry. PV: Can the pharmaceutical industry evolve based on its current organizational structure and incentives? Nosta: No, I don’t th...

    By John Nosta • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Agency Executive Roundtable

    Heavy is the Crown Without a doubt talent — recruitment, retention, and engagement — is the biggest challenge our agency executives face today. At the same time, technology, ideation, shared value, and time are also top of mind. Sharon Callahan. TBWA\WorldHealth. The first challenge that comes to...

    By PharmaVoice Team • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Brain Wave: Breakthroughs Bring New Hope to CNS

    In February 2018, FDA Commissioner Scott Gottlieb, M.D., emphasized the agency’s commitment to advancing the development of novel treatments for neurological conditions. His statement recognized the uneven progress made in certain diseases and pinpointed the complex nature of neurological conditi...

    By Kim Ribbink • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Red Zone: Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites

    Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit" sites and returned to them f...

    By WCG Clinical Services • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Medical affairs is in the midst of a transformation. The dynamics of the healthcare industry, the complexity of new science, and the breadth and sophistication of communication channels that physicians have available for accessing information, are expanding the role of medical affairs and reshapi...

    By PharmaVoice Team • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    For Their Transformative Inspiration and Influence Transformation is easy to define: a thorough or dramatic change in form or appearance. Transformation is much harder to achieve. For this special — and my favorite — issue we asked this year’s PharmaVOICE 100 to provide a short response to the st...

    By Taren Grom • Aug. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Change Agents

    Dr. Patrice Matchaba For Advancing the Quest for Global Access Title: Group Head of Global Health & Corporate Responsibility Company: Novartis AG Education: MD, University of Zimbabwe; Harvard Business School Program for Management Development A number of years ago, Dr. Patrice Matchaba’s mot...

    By PharmaVoice Team • Aug. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Clinical Experts

    Nariman Nasser For Creating Opportunities for Sites Title: VP, Site Engagement Company: Continuum Clinical Education: BS Microbiology, Arizona State University Hobbies: Swimming, biking, snowboarding, and anything outdoors that provides an adrenaline rush Associations: SoCRA, DIA, ACRP Social Med...

    By PharmaVoice Team • Aug. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Transforming for the Future By definition transformation means a thorough or dramatic change in form or appearance. Our thought leaders in this month’s cover story believe such a reshaping is necessary for the industry to have success in the future as biopharma companies must meet the business ch...

    By Taren Grom • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    A New Way to Deliver Proteins Paul Wotton, Ph.D., CEO of Sigilon Therapeutics, discusses his company’s approach for delivering cells that avoid immune detection. Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to ...

    By Paul Wotton • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    Sanofi Pasteur’s Approach to Vaccine Deployment Dr. Joël Calmet, Senior Director of Communications at Sanofi-Pasteur, discusses the company’s efforts to bring vaccines to underserved patient populations. PV: Why is patient access to vaccines in disadvantaged countries still a challenge? Calmet: D...

    By Dr. Joel Calmet • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Transformation: Is the Industry Ready?

    Although the pharma industry scored pretty low on a McKinsey scale of digital maturity, there is evidence that it is moving — perhaps only incrementally — toward a digital transformation that can streamline processes, generate collaboration, and coordinate data collection. The pharma sector, not ...

    By PharmaVoice Team • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Regenerative Medicine: The Dawn of a New Age of Biology

    Regenerative medicine could completely shake up the way diseases are treated. According to Reportlinker, the regenerative medicine market will reach an estimated $50.55 billion by 2025 thanks to the rapid growth of stem cell and gene therapy in developed markets. Scott Bruder, M.D., Ph.D., founde...

    By Kim Ribbink • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Red Zone: Personalized Medicine Requires Personalized Measurement

    CNS is the second largest area of pharmaceutical research, but the success rate has been low and approvals rare. In CNS drug development, it is common for investigational therapies to show promising effects in earlier trials, only to fail in the final stages of testing. Some of the reasons can be...

    By Sofija Jovic • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Understanding The Why Applying health psychology to deliver effective patient support As a health and clinical psychologist, I’ve spent the last ten years helping the healthcare industry address the self-management needs of patients living with long-term conditions. For the most part, this work h...

    By Kate Perry • June 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Riding the AI Wave It would be hard to identify a hotter trend right now than artificial intelligence and machine learning — a trend 60 years in the making since John McCarthy coined the term AI while leading a Dartmouth Summer Research Project. Merriam-Webster defines AI as: a branch of computer...

    By Taren Grom • May 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Upfront

    Acorda Rallies Parkinson’s Community Acorda Therapeutics has launched the “Live Well. Do Tell." initiative for the Parkinson’s disease community. Its goal is to encourage the community to improve conversations about Parkinson’s symptoms among the circle of care, including people with Parkinson’s,...

    By PharmaVoice Team • May 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    HealthTech

    Researchers Develop Nanovesicle Method for Tumor Treatment Trend Watch: Technology boosts cancer care. According to a report by Penn State News, a team of scientists working at Penn State University, Second Affiliated Hospital of Southeast University, and Jiangsu Cancer Hospital & Jiangsu Ins...

    By PharmaVoice Team • May 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    A Robotic Pill that Creates Oral Biologics Mir Imran, Chairman and CEO of Rani Therapeutics, talks about his company’s efforts to develop an injection-free, large-molecule delivery system. Biologics can only be administered through an injection, which can affect quality of life and patient compli...

    By Mir Imran • May 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    Making Sense of Antisense Technology Brett Monia, Ph.D., Chief Operating Officer and Senior VP, Antisense Drug Discovery and Translational Medicine at Ionis Pharmaceuticals, talks about the company’s pipeline of antisense technology products. Antisense technology presents an opportunity to manipu...

    By Brett Monia • March 1, 2018